Additionally, a study by Professor Ning Ren’s team at Zhongshan Hospital, Fudan University, found a statistically significant positive correlation has been observed between elevated serum levels of SLFN11 protein and the therapeutic efficacy of immune checkpoint blockade agents in the treatment of hepatocellular carcinoma (HCC) (4). The gene discussed is SLFN11; the disease is hepatocellular carcinoma.